SCHEMBL4603669

SCHEMBL4603669

CCC(=O)Nc1ccc(Oc2ccccc2Oc2ccccc2)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 5/20 0.53
PKM P14618 1/20 0.53
POLB P06746 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ATM Q13315 1/20 0.51
HSD17B10 Q99714 2/20 0.49
ADRA2C P18825 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
SERPINE1 P05121 1/20 0.48
MTNR1B P49286 2/20 0.48
MTNR1A P48039 1/20 0.48
GAA P10253 2/20 0.48
PYGM P11217 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604249 0.92 POLB (0.54) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4606034 0.88 IGF2BP2 (0.51) ALDH1A1KDM4EPKMHSD17B10GAA
SCHEMBL4605135 0.88 KDM4E (0.49) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4604342 0.88 KDM4E (0.49) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4604961 0.87 ALDH1A1 (0.48) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4603683 0.86 PYGM (0.62) SERPINE1PYGMMEN1KMT2ASMN1; SMN2
SCHEMBL4606539 0.86 MTNR1B (0.50) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4619861 0.86 KDM4E (0.47) ALDH1A1KDM4EPKMATMHSD17B10
SCHEMBL4606880 0.85 KMT2A (0.57) ALDH1A1KDM4EPKMPOLBL3MBTL1
SCHEMBL4603647 0.84 KDM4E (0.46) ALDH1A1KDM4EPKMPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 ALDH1A1 308/4885KDM4E 2898/4885PKM 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.